9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2012 New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer J Transl Med. 2012 Mar 15;10(1):48. [Epub ahead of print]
2. 2012 Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice Clin Cancer Res. 2012 Mar 15;18(6):1672-83. Epub 2012 Jan 30
3. 2012 Nine lives for T(H)9s? Nat Med. 2012 Aug 6;18(8):1177-8. doi: 10.1038/nm.2868
4. 2012 The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans Sci Transl Med. 2012 Aug 29;4(149):149ra120
5. 2012 Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 2012 Sep 13. doi: 10.1038/gt.2012.75. [Epub ahead of print]
6. 2012 Paths to stemness: building the ultimate anti-tumour T cell. Nat Rev Cancer. 2012 Oct;12(10):671-84. doi: 10.1038/nrc3322. Epub 2012 Sep 21
7. 2012 Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence J Immunol. 2012 Jul 15;189(2):767-76. Epub 2012 Jun 20
8. 2012 The power and pitfalls of IL-12 Blood. 2012 May 3;119(18):4096-7.
9. 2012 Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012 Mar 22;12(4):269-81.
10. 2012 Cellular Constituents of Immune Escape within the Tumor Microenvironment. Cancer Res. 2012 Jul 1;72(13):3125-30. Epub 2012 Jun 21
11. 2011 Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies J Immunother. 2011 May;34(4):343-52.
12. 2011 Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. 2011 Apr 15. Clin Cancer Res. 2011 Jul 1;17(13):4550-7. Epub 2011 Apr 15
13. 2011 Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice Cancer Immunol Immunother. 2011 May;60(5):671-83. Epub 2011 Feb 16
14. 2011 In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen experienced cells. Cancer Immunol Immunother. 2011 Feb 9. [Epub ahead of print], May;60(5):739-49, 2011
15. 2011 Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment Mol Ther. 2011 Apr;19(4):751-9. Epub 2011 Feb 1
16. 2011 Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. Epub 2011 Jan 31, 2011. Mar 1;29(7):917-24, 2011
17. 2011 Therapeutic cancer vaccines: are we there yet? Immunol Rev. Jan;239(1):27-44, 2011
18. 2011 T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Mol Ther advance online publication, December 14, 2010; in print Mar;19(3):620-6, 2011
19. 2011 Polymeric Structure and Host Toll-like Receptor 4 Dictate Immunogenicity of NY-ESO-1 Antigen in Vivo. J Biol Chem. 2011 Oct 28;286(43):37077-84. Epub 2011 Sep 7
20. 2011 Principles of Cancer Treatment: Cancer Immunotheray Cancer: Principle and Practice of Oncology (9th Edition). V.T. DeVita, S. Lawrence, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, pages 332-344, 2011
21. 2011 Repression of the DNA-binding inhibitor Id3 by Blimp1 limits CD8+ T cell memory formation. Nat Immunol. 2011 Nov 6;12(12):1230-7. doi: 10.1038/ni.2153
22. 2011 IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors J Clin Invest. 2011 Dec 1;121(12):4746-57. doi: 10.1172/JCI58814. Epub 2011 Nov 7
23. 2011 Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer. 2011 Oct 19;11(1):451. [Epub ahead of print]
24. 2011 A human memory T cell subset with stem cell-like properties Nat Med. 2011 Sep 18;17(10):1290-7. doi: 10.1038/nm.2446. [see commentary F Sallusto, A Lanzavecchia. Memory in disguise.Nat Med. 2011 Oct 11;17(10):1182-3.]
25. 2011 Th17 cells are long lived and retain a stem cell-like molecular signature Immunity. 2011 Dec 23;35(6):972-85. Epub 2011 Dec 15
26. 2011 Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res. 2011 Oct;21(10):1650-8. Epub 2011 Jul 27.
27. 2011 Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7
28. 2011 Imagining a cure: for cancer patients, close is not good enough The Scientist. Vol 25, Issue 4, Page 28-29, 2011
29. 2010 Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine J Immunother. 2010 Jul-Aug;33(6):626-9.
30. 2010 A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer J Immunol. 2010 Dec 13. [Epub ahead of print]PMID: 21149604
31. 2010 Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest. 2010 Dec 1;120(12):4273-88. doi: 10.1172/JCI43274. Epub 2010 Nov 15
32. 2010 Can antitumor immunity help to explain ‘‘oncogene addiction’’? Cancer Cell, 2010 Nov 16;18(5):403-5.
33. 2010 Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice J Clin Invest, 120 (11):3953–3968, 2010. doi:10.1172/JCI43490
34. 2010 Human effector CD8+ T cells derived from naïve rather than memory subsets possess superior traits for adoptive immunotherapy Blood. 2010 Oct 22. [Epub ahead of print]
35. 2010 Wnt/β-catenin signaling in T cell immunity and cancer immunotherapy Clin Cancer Res. 2010 Oct 1;16(19):4695-701. Epub Aug 5. 2010.
36. 2010 IFN-g-inducible lysosomal thiol reductase (GILT) accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1 J Immunol. 2010 Sep 1;185(5):2828-35. Epub 2010 Jul 28
37. 2010 CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res, 2010 Dec 15;16(24):6122-31. Epub 2010 Jul 28, 2010.
38. 2010 Tumor-specific CD8+ T cells expressing IL-12 eradicate established cancers in lymphodepleted hosts Cancer Res. 2010 Sep 1;70(17):6725-34. Epub 2010 Jul 20.2010
39. 2010 Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive cell transfer immunotherapy of cancer Cancer Res. 2010 Jul 14
40. 2010 Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells Blood. 2010 Jul 14. [Epub ahead of print]PMID: 20631379 [PubMed - as supplied by publisher]Related citations
41. 2010 Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase J Immunol, Apr 28. [Epub ahead of print] 2010
42. 2010 T(H)17 cells in tumour immunity and immunotherapy Nat Rev Immunol. 10(4):248-56, 2010.
43. 2010 Naïve tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma J Exp Med, 207(3): 651-667,2010.
44. 2010 Eradication of large, established melanoma after transfer and in vivo priming of tumor-reactive cytotoxic CD4+ T cells J Exp Med, 207(3): 637-650, 2010
45. 2010 Development of replication-defective lymphocytic choriomeningitis virus vectors for induction of potent CD8+ T cell immunity Nature Med, Published online, 7 February, 2010
46. 2010 IFN-g-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T cell-mediated injury of vascular endothelial cells Eur J Immunol. 2010 Jan 4. [Epub ahead of print]
47. 2010 Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells J Immunother. 2010 Jan;33(1):1-7
48. 2009 Suppressors of Cytokine Signaling (SOCS) in T cell differentiation, maturation and function. Trends Immunol Trends Immunol. 2009 Oct 29. [Epub ahead of print] PMID: 19879803
49. 2009 T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity Immunity. 2009 Oct 28. [Epub ahead of print] PMID: 19879162
50. 2009 Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity Proc Natl Acad Sci (USA), 2009 Oct 13;106(41):17469-74.Sep 24 [Epub ahead of print], 2009
51. 2009 Does IL-17 cause T cells to grow? Blood, Jul 9;114(2):231-2, 2009
52. 2009 Touloukian. High avidity autoreactive CD4+ T cells cross-prime host CTL, overcome Tregs and mediate tumor destruction J Immunother Sep;32(7):677-88, 2009
53. 2009 Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination Blood. 2009 Jun 26. [Epub ahead of print], PMID: 19561320 [PubMed - as supplied by publisher].
54. 2009 Schoenberger Nat Med. doi:10.1038/nm0709-731
55. 2009 Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med. 15, 808 – 813, 2009. [Epub ahead of print] PMID: 19525962, 2009
56. 2009 Viral sequestration of antigen subverts cross presentation to CD8+ T cells PLoS Pathog. 2009 May;5(5):e1000457. PMID: 19478869.
57. 2009 Type 17 CD8+ T cells display enhanced anti-tumor immunity Blood, 114(3):596-9. Epub May 26, 2009
58. 2009 High affinity T cell receptor gene therapy breaks tolerance and elicits autoimmunity and cancer regression. 2009 Blood. 2009 May 18. [Epub ahead of print] PMID: 19451549
59. 2009 Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009 May;116(5):981-989.e1. PMID: 19410956
60. 2009 Adoptive T cell therapy of cancer Curr Opin Immunol. 2009 Apr;21(2):187-9, PMID: 19328668
61. 2009 Adoptive immunotherapy of cancer using CD4+ T cells Curr Opin Immunol, 2009, Apr;21(2):200-8, PMID: 19285848
62. 2009 Pharmaceutical induction of T cell memory: better living through chemistry Sci Transl Med. Dec 16;1(11):11ps12, 2009.
63. 2008 Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers Blood, Sep 17. [Epub ahead of print], 2008
64. 2008 Cancer Immunology Cancer: Principle and Practice of Oncology (8th Edition). V.T. DeVita, S. Lawrence, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, pages 139-161, 2008
65. 2008 Rosenberg. Tumor Immunology Fundamental Immunology (7th Edition). W.E. Paul, Ed. Lippincott, Philadelphia, In Press, 2008.
66. 2008 MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes J Immunol. 2008 Dec 1;181(11):7843-52
67. 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol, 2008 Nov 10;26(32):5233-9. Epub 2008 Sep 22
68. 2008 Cancer immunotherapy N Engl J Med, 359(10):1072. 2008
69. 2008 Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 2008;14 5610-5618
70. 2008 TSCOT Thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation PLoS Biol 6(8): e191. doi:10. 1371/journal.pbio.0060191
71. 2008 Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6. Epub 2008 Jun 3
72. 2008 Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition Gene Ther. May 22, 2008. [Epub ahead of print]PMID: 18496571 [PubMed - as supplied by publisher]
73. 2008 Adoptive Cell Transfer: A Clinical Path to Effective Cancer Immunotherapy Nat Rev Cancer. 2008 Apr;8(4):299-308
74. 2008 Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 15;112(2):362-73, Epub Mar 19, 2008.
75. 2008 IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy Blood. 2008 Jun 1;111(11):5326-33. Epub 2008 Feb 14
76. 2008 Immunological ignorance of vascular endothelial cells expressing minor histocompatibility antigen Blood. May 1;111(9):4588-95. Epub 2008 Jan 14
77. 2008 T cell receptor gene therapy of established tumors in a murine melanoma model. J Immunotherapy. 2008 Jan;31(1):1-6
78. 2007 Structures of MART-126/27-35 peptide/HLA-A2 complexes reveal broad T cell cross-reactivity in the absence of structural homology J Mol Biol. 2007 Oct 5;372(5):1123-36. Epub 2007 Jul 26
79. 2007 Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling J Clin Invest. 2007 Aug;117(8):2197-204
80. 2007 Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007 Sep 15; 13 (18 Pt 1): 5280-9
81. 2007 Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling Cancer Res. 2007 Mar 15;67(6):2425-9.
82. 2007 Hematopoietic stem cells promote the expansion and function of adoptively transferred anti-tumor CD8+ T cells J Clin Invest. 2007 Feb;117(2):492-501
83. 2006 Cross-priming utilizes antigen not available to the direct presentation pathway Immunology. 2006 Sep;119(1):63-73. Epub 2006 June 8.
84. 2006 Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine. 2006 Jun 12;24(24):5110-8. Epub 2006 May 6.
85. 2006 Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006 May 1;66(9):4904-12.
86. 2006 Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma Clin Cancer Res. 2006 Apr 15;12(8):2526-37
87. 2006 Adoptive immunotherapy for cancer: building on success Nat Rev Immunol. 2006 May;6(5):383-93
88. 2006 Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006 May 1;176(9):5255-66.
89. 2006 Increased intensity lymphodepletion and adoptive immunotherapy: How far can we go? Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
90. 2006 Programming CD8(+) T cells for effective immunotherapy Curr Opin Immunol. 2006 Jun;18(3):363-70. Epub 2006 Apr 17
91. 2006 Altered CD8+ T-cell responses when immunizing with multiepitope peptide vaccines J Immunother, 29(2):224-31, 2006
92. 2006 Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T cell responses Blood, Blood. Jun 15;107(12):4597-605, 2006
93. 2006 The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor Cancer Res, 66(2):1132-8, 2006
94. 2006 De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model Cancer Res, 66(2):1105-13, 2006
95. 2006 Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant J Immunol. 2006 May 1;176(9):5213-22.
96. 2006 Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases Mol Cancer Ther. 2006 Oct;5(10):2592-9
97. 2006 Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Science, 314(5796):126-9. Epub Aug 31, 2006.
98. 2006 CTLA-4 dysregulation of self/tumor-reactive CD8+ T cell function is CD4+ T cell-dependent Blood. 2006 Aug 1
99. 2006 CD8+ T-cell memory in tumor immunology and immunotherapy Immunol Rev. 2006 Jun;211:214-24
100. 2005 Use of standard criteria for assessment of cancer vaccines Lancet Oncol, 6(1):3-4, 2005
101. 2005 Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing Cancer Res, 65(22): 10569-77, 2005
102. 2005 Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma J Immunol, 75(9):6169-76, 2005
103. 2005 Glucocorticoids do not inhibit anti-tumor activity of activated CD8+ T cells J of Immunotherapy, 28(6):517-24, 2005
104. 2005 Removal of homeostatic cytokine sinks by lymphodepletion enhances autoimmunity and the effectiveness of adoptively transferred tumor-specific CD8+ T cells J Exp Med, 202(7):907-12, 2005
105. 2005 High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Mol Ther. Sep 1, 2005
106. 2005 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol., 23(25):6043-53, 2005
107. 2005 Central memory tumor-reactive CD8+ T cells confer superior anti-tumor immunity compared to effector memory T cells Proc Natl of Sci (USA), 102(27):9571-6, 2005
108. 2005 Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells J Clin Invest, 115(6):1616-26, 2005
109. 2005 Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stablility of the peptide/MHC complex: implications for vaccine design J Immunol, 174(8): 4812-20, 2005
110. 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol, 23(10): 2346-57, 2005
111. 2005 Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy Cur Opin in Immunol, 17(2): 195-201, 2005.
112. 2005 Bcl-2 over-expression results in prolonged survival of human tumor specific T cells and leads to enhanced adoptive immunotherapy Cancer Res, 65(5): 2001-8, 2005
113. 2005 CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells J Immunol, 174(5): 2591-601, 2005
114. 2005 CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 J Immunother, 28(2):120-8, 2005
115. 2005 Sinks, Suppressors and Antigen Presenters: How lymphodepletion enhances T cell mediated tumor therapy Trends in Immunology, 26(2): 111-7, 2005
116. 2005 Immune Selection of Hot-Spot {beta}2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. J Immunol,174(3):1462-1471, 2005
117. 2005 Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function J Exp Med,.201(1):139-48, 2005.
118. 2005 Cancer Immunology Cancer: Principle and Practice of Oncology (7th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 139-161, 2005
119. 2005 Therapeutic Vaccines Cancer: Principle and Practice of Oncology (7th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 2846-56, 2005.
120. 2004 Metastable peptide/MHC complexes impair in vivo induction of tumor/self-specific T cell responses J Clin Invest, 114(4):551-9, 2004
121. 2004 Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer J Leukoc Biol, 76(2):333-7, 2004
122. 2004 Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines Vaccine, 22(11-12):1537-44, 2004.
123. 2004 L-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A, 101(7):1969-74, 2004
124. 2004 Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo Cancer Res, 15;64(18):6783-90, 2004
125. 2004 Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol, 173(12):7209-16, 2004
126. 2004 Reply to "Cancer vaccines: pessimism in check". Nat Med, 2004 Dec;10(12):1279-80
127. 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med, 10(9):909-15, 2004
128. 2003 Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways Nat Med, 9(1):33-9, 2003.
129. 2003 Immune evasion by murine melanoma mediated through CC chemokine receptor-10 J Exp Med, 198(9):1337-47, 2003
130. 2003 Cell transfer therapy for cancer: Lessons from sequential treatments of a patient with metastatic melanoma J Immunother, 26(5):385-393,
131. 2003 High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens J Immunol, 171:3287-3295, 2003
132. 2003 Induction of tumor regression and autoimmunity by reversing the functionally tolerant state of self-reactive CD8+ T cells J Exp Med, 198 (4): 569-580, 2003
133. 2003 Recominant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma Clinical Cancer Res, 9(8): 2973-80, 2003.
134. 2003 Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens J Immunother, 26(4):349-56, 2003
135. 2003 DNA vaccines and apoptosis: to kill or not to kill? J Clin Invest, 112(1):22-4, 2003.
136. 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen-4 blockade in patients with metastatic melanoma Proc Natl Acad Sci U S A, 100(14):8372-8377, 2003
137. 2003 Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther, 14:709-714, 2003
138. 2003 Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor antigen, OA1 J Immunol, 170(3):1579-85, 2003
139. 2002 Cancer regression and autoimmunity following clonal repopulation with anti-tumor lymphocytes and non-myeloablative conditioning Science, 298(5594): 850-854, 2002
140. 2002 Expression of a “self-” antigen by tumor cells in vivo enhances human tumor antigen-specific CD4+ T cell function Cancer Res, 62(18):5144-7, 2002
141. 2002 Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma J Clin Oncol, 20(1):142-152, 2002
142. 2002 Assumptions of the tumor escape hypothesis Seminars in Cancer Biology, 12(1):81-86, 2002.
143. 2002 Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother, 25(3):202-6, 2002
144. 2002 Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells J Clin Invest, Jun;109(11):1463-70, 2002
145. 2002 Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness Cancer Res, Jul 1;62(13):3581-3586, 2002
146. 2002 Cancer vaccines: Progress reveals new complexities J Clin Invest, 110(3): 289-294, 2002.
147. 2002 Natural selection of tumor variants in the generation of "tumor escape" phenotypes Nat Immunol, 3(11):999-1005, 2002
148. 2002 Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC Prostate, 53(3):183-91, 2002
149. 2002 MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells Cancer Gene Therapy, 9(11):946-50, 2002
150. 2001 B16 as a mouse model for human melanoma Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.1.
151. 2001 Immunization against endogenous retroviral tumor-associated antigens Cancer Res 61, 7920-7924, 2001
152. 2001 Newer approaches in cancer treatment: Therapeutic cancer vaccines Cancer: Principle and Practice of Oncology (6th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 3195-3217, 2001
153. 2001 Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy J Exp Med, 194(4), 481-90, 2001
154. 2001 Hierarchy, tolerance, and dominance in the antitumor T‑cell response J Immunother, 24(3):193‑4, 2001.
155. 2001 B16 as a mouse model for human melanoma In Current Protocols in Immunology. Ed. Ada Kruisbeek, 2001
156. 2001 Vaccines to die for Nat Biotechnol, 19(6):527‑8, 2001
157. 2001 Creating therapeutic cancer vaccines: notes from the battlefield Trends In Immunol, (Formerly Immunology Today), 22(1): 5-7, 2001
158. 2001 Countering the 'counterattack' hypothesis Nat Med, 7(3): 259-260, 2001
159. 2001 Essentials of modern oncologic science: Essentials of immunology Cancer: Principle and Practice of Oncology (6th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 43-73, 2001
160. 2001 RNA vaccines Encyclopedia Of Molecular Medicine. (John Wiley & Sons). 2843, 2001
161. 2001 Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor associated antigen. Ca Res, 61(22):8100-8104, 2001
162. 2001 Immunization and the induction of the anti-tumor T cells. J Immunol, 168(1):338-47, 2001
163. 2000 Autoimmunity and the immunotherapy of cancer: targeting the “self” to destroy the “other”. Crit Rev Immunol, 20(6):433‑50, 2000.
164. 2000 Poxviruses as vectors for cancer immunotherapy In Cancer Vaccines and Immunotherapy, Ed. PL Stern, PCL Beverly and MW Carroll. Cambridge University Press, (Cambridge UK), 47-61, 2000
165. 2000 Identification of a CD11b + / Gr‑1 + / CD31 + myeloid progenitor capable of activating or suppressing CD8+ T cells Blood, 96(12): 3838‑3846, 2000.
166. 2000 Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity Current Opinion in Immunology, 12(5): 597-603, 2000
167. 2000 Dose-dependent and schedule-dependent effects of IL-12 on antigen-specific CD8 responses J Interferon Cytokine Res, 20(6): 589-96, 2000.
168. 2000 Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol, 165(2): 1153‑1159, 2000
169. 2000 Antitumor efficacy of tumor‑ antigen‑ encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development World J Urol, 18(2):136‑42, 2000
170. 2000 Not so fas: Re-evaluating the mechanisms of immune priviledge and tumor escape Nat Med, 6(5): 493-495, 2000.
171. 2000 An autologous oral DNA vaccine protects against murine melanoma Proc Natl Acad Sci (USA), 97(10): 5792-5497, 2000
172. 2000 Antiangiogenic gene therapy of cancer using systemic administration of an adenoviral vector carrying the endostatin gene Cancer Res, 60(6): 1503-1506, 2000
173. 2000 Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for immunotherapy J Exp Med, 191(7): 1221‑1232, 2000
174. 2000 Identification of a DRB1*0401-restricted epitope for gp100 using DR4-IE transgenic mice J Immunol, 164(7): 3535-3542, 2000.
175. 2000 The future of interleukin-2: Enhancing therapeutic anticancer vaccines. Cancer Journal from Sci Amer, 6: 76-80, 2000.
176. 2000 The Promise of Nucleic Acid Vaccines Gene Therapy, 7(2): 89-92, 2000.
177. 2000 Genetic vaccination with “self” Tyrosinase-Related Protein 2 causes melanoma eradication but not vitiligo Cancer Res, 60(2): 253‑258, 2000.
178. 2000 Enhancement of tumor‑specific immune response with plasmid DNA replicon vectors. Cancer Res, 60(1): 51‑55, 2000
179. 2000 Cutting Edge: CD4+ T cell control of CD8+ T cell reactivity to an immunogenic model tumor antigen J Immunol: Cutting Edge, 164(2): 562-565, 2000.
180. 2000 Cancer Vaccines: Basic Principles: General concepts and preclinical studies Principles and Practice of the Biologic Therapy of Cancer. S.A. Rosenberg, Ed., JB Lippincott, Philadelphia, 571-584, 2000.
181. 2000 Flu: The story of the great influenza pandemic of 1918 and the search for the virus that caused it. By Gina Kolata Book Review. Nat Med, 6(1): 12-13, 2000
182. 2000 Peptide vaccines for the treatment of melanoma In Peptide-Based Cancer Vaccines. Ed. WM Kast, Landes Bioscience, (Georgetown, TX), 190-199, 2000
183. 1999 Developing recombinant and synthetic vaccines for the treatment of melanoma. (Edited by Edison Liu). Current Opinion in Oncology, 11(1):50-7, 1999
184. 1999 Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition J Immunol, 162(6): 3273-3279, 1999.
185. 1999 Unopposed production of granulocyte‑macrophage colony‑stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen‑presenting cell maturation J Immunol, 162(10): 5728‑5737, 1999
186. 1999 Recombinant virus vaccination against self antigens using "anchor-fixed" immunogens Cancer Res, 59(11): 2536‑2540, 1999
187. 1999 Cancer therapy using a self-replicating RNA vaccine. Nat Med, 5(7): 823-827, 1999
188. 1999 Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine J Immunol, 163(3): 1690‑1695, 1999
189. 1999 The antiviral enzymes PKR and RNase L suppress gene expression from viral and non‑viral based vectors. Nucleic Acids Res, 27(22): 4369‑4375, 1999.
190. 1999 Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunotherapy, 22(6): 489-496, 1999
191. 1999 DNA and RNA-based vaccines: principles, progress and prospects Vaccine, 18(9-10):765-77, 1999
192. 1999 Tumor variability and sensitivity to T and NK cells: Implications for cancer immunotherapy Jap J Cancer Res., Gann Monograph on Cancer Research 48: 105-115, 1999.
193. 1999 Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model Int J of Cancer, 80:781-90, 1999
194. 1999 Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified SV40-T antigen. J National Cancer Institute, 91(2):169-75, 1999. 1999
195. 1999 Melanoma cells do not express Fas (Apo-1/CD95) ligand Cancer Res, 59(1):59‑62, 1999
196. 1999 Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes Proc Natl Acad Sci (USA), 96(6):2982-87, 1999
197. 1998 Immunizing patients with metastatic melanoma using recombinant adenovirus encoding MART-1 or gp100 melanoma antigens J Natl Cancer Inst, 90(24):1894-1900, 1998
198. 1998 Construction and characterization of a triple-recombinant vaccinia virus encoding a model tumor antigen, B7-1 and Interleukin-12 J National Cancer Institute, 90(24):1881-7, 1998
199. 1998 Apoptotic death of CD8+ T lymphocytes after immunization: Induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol, 161(10):5313-20, 1998.
200. 1998 CD40 Ligand/Trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge J Immunol, 161(9):4563-71, 1998
201. 1998 T cell - tumor cell: A fatal interaction? Cancer Immunol and Immunotherapy, 47(2): 65‑71, 1998
202. 1998 Cancer Vaccines ‘98: A Reductionistic Approach Molecular Medicine Today, 4(8): 327, 1998.
203. 1998 Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization J Exp Med, 188(6):1075‑82, 1998.
204. 1998 Transfectant Influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer Virology, 249(1):89‑97, 1998
205. 1998 Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization J Immunol Methods, 214(1-2): 51-62,1998
206. 1998 gp100/pmel 17 is a murine tumor rejection antigen: Induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand J Exp. Med, 188(2): 277-86, 1998
207. 1998 Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma Nat Med, 4(3): 321-28,1998.
208. 1998 The use of recombinant poxviruses as a paradigm for the development of anti-cancer vaccines Molecular Approaches to Tumor Immunotherapy. World Scientific Press, London, Y. Liu, Ed.. pp 236-300, 1998
209. 1997 Enhancement of cellular immunity in melanoma patients immunized with a MART-1 melanoma antigen peptide The Cancer Journal from Scientific American, 3(1):37-44, 1997.
210. 1997 Natural killer cells kill autologous 2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy Proc Natl Acad Sci USA, 94:13140‑45, 1997
211. 1997 Enhancing the efficacy of recombinant anti-cancer vaccines with prime/boost regimens that employ two different vectors J Natl Cancer Inst, 89(21):1595-1601, 1997
212. 1997 Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro J Immunother, 20(4):276-86, 1997.
213. 1997 Identification of a Kb-restricted CTL epitope of -galactosidase: Potential use in the development of immunization protocols for "self" antigens Immunomethods, 12:117-23, 1997
214. 1997 Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine Proc Natl Acad Sci (USA), 94(7): 3183‑88 1997
215. 1997 Route of administration and the efficacy of recombinant vaccinia, fowlpox and adenoviruses. J Natl Cancer Inst, 89(5):390-92, 1997
216. 1997 Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model Vaccine, 15(4):387‑94, 1997
217. 1997 Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART-1 and gp100 J Immunotherapy, 20(1): 15-25, 1997
218. 1997 Newer approaches in cancer treatment: Cancer vaccines Cancer: Principle and Practice of Oncology (5th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 3023-43, 1997
219. 1997 Essentials of modern oncologic science: Essentials of immunology Cancer: Principle and Practice of Oncology (5th Edition). V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, 47-75, 1997
220. 1996 Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol, 397:7-13, 1996
221. 1996 Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases J Immunol, 156(1):238-45, 1996
222. 1996 Therapeutic anti-tumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen J Immunol, 156(1): 224-31, 1996.
223. 1996 Antigen processing and presentation Tumor Immunology: Immunotherapy and Cancer Vaccines. Edited by A.G. Dalgleish and M.J. Browning. Cancer, Clinical Science in Practice. Cambridge University Press, 39-68, 1996
224. 1996 The new vaccines: Building viruses capable of eliciting anti-tumor immunity Current Opinion in Immunol, 8(5): 658-63, 1996.
225. 1996 Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines Cancer Res, 56:2832-36, 1996
226. 1996 Interleukin-12 is an effective adjuvant to recombinant vaccinia virus based tumor vaccines: Enhancement by simultaneous B7-1 expression J Immunol, 156(9):3357-65, 1996
227. 1996 Loss of functional 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy J Natl Cancer Inst, 88(2):100-8, 1996.
228. 1996 Commentary: Recombinant anti-cancer vaccines The Cancer Journal from Scientific American, 2(1):16-18, 1996
229. 1995 Antigen processing in vivo and the elicitation of primary CTL responses J Immunol, 154(9):4414-22, 1995.
230. 1995 Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses Cancer Res, 55(8):1741-47, 1995
231. 1995 Molecular characterization of defective antigen processing in human prostate cancer. J Nat Can Inst, 87(4):280-85, 1995.
232. 1995 Active immunotherapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen J Immunol, 154(9):4685-92, 1995
233. 1995 IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases . J Immunol, 154(10):5282-92, 1995.
234. 1995 Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes Cancer Res, 55:3149-57, 1995
235. 1995 Anti-tumor Activity of Cytotoxic T Lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen J Immunother, 18(3):139-46, 1995
236. 1995 HLA associations in the antitumor response against malignant melanoma J Immunother, 18(4):242-52, 1995
237. 1995 The next wave of recombinant and synthetic anti-cancer vaccines Seminars in Cancer Biology, 6(6):337-47, 1995
238. 1995 Treatment of established murine tumor metastases by immunization with recombinant adenovirus encoding a model tumor-associated antigen. Surg Forum. 46:459-62, 1995
239. 1995 Principles of tumor immunity: Biology of cellular immune responses Biologic Therapy of Cancer. V.T. DeVita, S. Hellman, and S.A. Rosenberg, Eds., J.B. Lippincott, Philadelphia, pp 3-37, 1995
240. 1995 Immunization with recombinant vaccinia virus encoding the costimulatory molecules B7-1 and/or B7-2 and a model tumor antigen mediates tumor regression and prolongs survival Surg Forum. 46:483-485, 1995
241. 1995 Vaccines against virally induced cancers FEBS Letters, 377(2):281, 1995
242. 1995 Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic cytolytic T lymphocytes J Immunol, 154(9):4651-57, 1995
243. 1995 Defective MHC class I expression in a sarcomatoid renal cell carcinoma cell line J Immunother, 17(4):222-28, 1995.
244. 1994 Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon- in a multidrug-resistant small cell lung cancer line Lymphokine Cytokine Res, 13(2):125-31, 1994
245. 1994 Treatment of established lung metastases with tumor-infiltrating-lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-. J Immunol, 152(7):3500-13, 1994.
246. 1994 Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol, 68(6):3505-11, 1994
247. 1994 Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines J Immunother, 16:13-23, 1994
248. 1994 Insertion signal sequence fused to a minimal peptide elicits specific CD8+ T cell responses and prolongs survival of thymoma-bearing mice Cancer Res, 54(15): 4155-61, 1994
249. 1994 Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest Cancer Immunol Immunother, 39(2):73‑83, 1994
250. 1994 Antigen presentation by IFN- releasing tumor cells Cytokine Induced Tumor Immunogenicity. Eds., G Forni, R Foá, A Santoni and L Frati. Academic Press, London, 22:307-28, 1994
251. 1994 Enhancing the recognition of tumor associated antigens Folia Biologica (Prague), 40(1-2):74-88, 1994.
252. 1993 Detection of shared human melanoma T cell antigens by providing HLA molecules by vaccinia virus. J Immunol, 151(3): 1410-18, 1993
253. 1993 The multiple uses of viruses for studying antigen processing Seminars in Virology. 4(2): 109-16, 1993
254. 1993 Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility comp class I J Immunother, 14(3):182-90, 1993
255. 1993 Retroviral transduction of interferon- cDNA into a non-immunogenic MHC class I deficient murine fibrosarcoma: Generation of T cells capable of treating established parental metastatic tumor Cancer Immunol and Immunotherapy, 37(5): 286-92, 1993
256. 1993 T cell recognition of human melanoma antigens J Immunotherapy, 14(2): 88-93, 1993.
257. 1993 Identification of human cancers deficient in antigen processing J Exp Med, 177(2): 265-272, 1993
258. 1993 Cytokine secretion by genetically modified non immunogenic murine fibrosarcoma: Tumor inhibition by IL-2 but not TNF-. J Immunol, 150(3): 896-908, 1993.
259. 1992 Antigen processing and presentation An update. Biologic Therapy of Cancer Updates. eds. VT DeVita, S Hellman and SA Rosenberg. JB Lippincott Co. Publishers. Philadelphia, PA. 2(2): 1-10, 1992.
260. 1992 A nonimmunogenic sarcoma transduced with the cDNA for mIFN- elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability J Exp Med, 175(6): 1423-32, 1992.
261. 1992 Gene-modification corrects an antigen presentation defect in a nonimmunogenic sarcoma and elicits CD8+ T cells reactive against the wild-type tumor: Implications for the immunotherapy of cancer J Immunotherapy. 11(2): 140, 1992
262. 1992 In vivo activity of TNF-" mutants: Secretory but not membrane bound TNF-" mediates the regression of retrovirally transduced murine tumor J Immunol, 149(6): 2076-81, 1992
263. 1991 Murine tumor cells transduced with the gene for tumor necrosis factor-: Evidence for paracrine immune effects of tumor necrosis factor against tumors J Immunol, 146(9): 3227-34, 1991
264. 1991 Defective presentation of endogenous antigens by a murine sarcoma: Implications for the failure of an anti-tumor immune response J Immunol, 147(4): 1453-59, 1991
265. 1991 The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man Metabolism, 40(1): 59-65, 1991
266. 1985 Biopsychosocial characteristics of children who later murder: a prospective study. Am. J Psychiatry, 142(10): 1161-67, 1985
267. 1985 Three case reports of a single homicidal adolescent Am J Psychiatry, 142(3): 388


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.